Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …

Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …

Background The use of immune-checkpoint inhibitors in cancer treatment has become
increasingly common, resulting in an increase in the incidence of related side effects …

Background Expression of programmed cell death-ligand 1 (PD-L1) is known to be a
mechanism whereby cancer can escape immune surveillance, but little is known about …

Background Programmed cell death 1 receptor–ligand interaction is a major pathway often
hijacked by tumors to suppress immune control. The aim of this retrospective study was to …

Purpose Cancer cachexia (CC) is commonly seen in advanced lung cancer patients and
associated with poor prognosis. However, little is known about CC that develops during …

The most common event responsible for resistance to first-and second-generation (1st and
2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of …

9005 Background: MET exon 14 skipping (MET ex14) mutations-reported in 3~ 4% of
NSCLC patients (pts)-are activating, sensitive to MET inhibition and can be conveniently …

Introduction Interstitial pneumonia (IP) is one of the most common and poor prognostic
comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab …

As the development of resistance to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) has become an issue of concern, identification of the mechanisms …